

CEO Ronan O’Caoimh Increases Shareholding in Trinity Biotech

DUBLIN, Ireland, Nov. 29, 2018 — Trinity Biotech plc (Nasdaq: TRIB), today announced that Ronan O’Caoimh, CEO of Trinity Biotech, has increased his shareholding in Trinity Biotech by the acquisition of 425,000 ADRs. As a result of this transaction, Mr. O’Caoimh’s shareholding in Trinity Biotech has increased from 1,339,374 ADRs to 1,764,374 ADRs which represents 8.4% of the company’s share capital excluding the impact of share options. The increase in shareholding was due to shares purchased in the open market. This was in addition to the purchase of 430,000 ADRs by Ronan O’Caoimh which was announced in June 2018.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company’s website: www.trinitybiotech.com.

Contact:

Trinity Biotech plc

Kevin Tansley

(353)-1-2769800

E-mail: kevin.tansley@trinitybiotech.com

Lytham Partners LLC

Joe Diaz, Joe Dorame & Robert Blum

602-889-9700

